Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KPO1143
- Development stage
- Preclinical
- Lead developer
- KinoPharma
- Modality
- Small Molecules
01
Overview
KPO1143 is a preclinical small-molecule drug candidate developed by KinoPharma for the treatment of **Alzheimer's disease** (AD). It is under evaluation in collaborative research with Japan's National Institutes for Quantum and Radiological Science and Technology to assess its pharmacological actions in AD models, including administration to animal models for efficacy studies. The compound is part of KinoPharma's pipeline, which primarily focuses on kinase-targeting small molecules, though specific details on its mechanism for AD remain undisclosed in available sources.[1][3][5]
- Other names
- KinoPharma Alzheimer's Treatment
02
Targets
MAPT (Microtubule-associated protein tau)
Beyond the preview
Go deeper on KPO1143.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KPO1143.